Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

NEXT STORY
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting
PREV STORY
Skylight Health Appoints Andrew Elinesky as Chief Financial Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER ...

author_avatar
NASDAQ Market News

Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences

author_avatar
NASDAQ Market News

The Global Rapid Diagnostics Market is expected to grow from USD 18,236.13 Million in 2018 to USD 38,256.52 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.16%

author_avatar
NASDAQ Market News